Widely used:Recently Viewed
Clear All
$58 Mln
--
0.53
--
0
-66.81 %
--
0 %
2.32
-1849843
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Shattuck Labs Inc (STTK)
| -82.89 | -64.43 | -67.03 | -10.95 | -61.32 | -- | -- |
|
BSE Sensex*
| 12.20 | -0.16 | 1.32 | 22.81 | 11.05 | 16.56 | 11.80 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
Shattuck Labs Inc (STTK)
| 210.00 | -72.97 | -83.76 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$58.23 Mln
$4.12 Mln
$0.00 Mln
$105.34 Mln
$3.82 Mln
High
$1.15 - 11.76
47,727,300
NASDAQ: STTK
Austin, TX
https://www.shattucklabs.com
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the... treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. Read more
The total asset value of Shattuck Labs Inc (STTK) stood at $ 144 Mln as on 30-Jun-24
The share price of Shattuck Labs Inc (STTK) is $1.22 (NASDAQ) as of 04-Oct-2024 16:25 EDT. Shattuck Labs Inc (STTK) has given a return of -61.32% in the last 3 years.
Shattuck Labs Inc (STTK) has a market capitalisation of $ 58 Mln as on 04-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Shattuck Labs Inc (STTK) is 0.53 times as on 04-Oct-2024, a 83% discount to its peers’ median range of 3.12 times.
Since, TTM earnings of Shattuck Labs Inc (STTK) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Shattuck Labs Inc (STTK) and enter the required number of quantities and click on buy to purchase the shares of Shattuck Labs Inc (STTK).
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
The CEO & director of Dr. Taylor H. Schreiber M.D., Ph.D.. is Shattuck Labs Inc (STTK), and CFO & Sr. VP is Dr. Taylor H. Schreiber M.D., Ph.D..
There is no promoter pledging in Shattuck Labs Inc (STTK).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Shattuck Labs Inc (STTK) | Ratios |
|---|---|
|
Return on equity(%)
|
-66.81
|
|
Operating margin(%)
|
-2195.81
|
|
Net Margin(%)
|
-2067.99
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Shattuck Labs Inc (STTK) was $0 Mln.
$-0.06
